Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Curanex Pharmaceuticals Inc. ( (CURX) ) has provided an announcement.
On March 2, 2026, Curanex Pharmaceuticals Inc. approved a four-year executive employment agreement for CEO and President Jun Liu, effective March 1, 2026, formalizing his ongoing leadership since February 2024 with an annual base salary of $393,600, equity incentive eligibility, comprehensive benefits, and an automobile lease allowance, alongside defined severance protections for termination without cause or for good reason. On the same date, the company entered into an at-will executive employment agreement with COO Liqin Xie, effective March 1, 2026, providing a $180,000 annual base salary, equity and benefits eligibility, and three months’ salary and accelerated vesting upon termination without cause, while both executives are bound by non-compete, non-solicitation, non-disclosure, and invention assignment covenants that aim to stabilize leadership and safeguard the company’s intellectual property and competitive position.
The CEO agreement also specifies differing outcomes if Mr. Liu’s employment ends due to death, disability, voluntary resignation, or termination for cause, with full vesting of unvested equity upon a qualifying separation or termination without cause. The COO agreement similarly details compensation and benefit treatment upon death, disability, voluntary resignation, or termination for cause, with severance and immediate vesting only if the company terminates without cause, underscoring Curanex’s effort to balance executive retention with shareholder and operational protections.
More about Curanex Pharmaceuticals Inc.
Curanex Pharmaceuticals Inc. operates in the pharmaceutical and biotechnology industry as a publicly listed company, focusing on research and development oversight, clinical and regulatory coordination, and capital markets activities. Its executive team is tasked with driving corporate strategy, preclinical and clinical operations, and cross-functional management to support the company’s growth and operational execution.
Average Trading Volume: 4,446,536
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.31M
See more insights into CURX stock on TipRanks’ Stock Analysis page.